Intelivation's 3D-Printed Implant Aims to Reshape Spinal Fusion Surgery

PLYMOUTH MEETING, PA – June 25, 2026 – Intelivation Technologies, a research-focused medical device company, today announced the first successful clinical use of its Advantage-C™ Ti3D Cervical Interbody Device. The procedure, performed by Dr. Victor Hsu of Rothman Orthopaedics in Philadelphia, marks a pivotal moment for the company and a potential leap forward in the treatment of degenerative neck conditions that affect millions annually.

The device, a 3D-printed titanium cage, represents the culmination of advanced material science and engineering aimed at solving long-standing challenges in spinal fusion surgery. While the announcement of a 'first use' is a common milestone in the med-tech industry, the underlying technology of the Advantage-C™ Ti3D suggests a more significant shift is underway, one that leverages intricate design to work more intelligently with the body's own healing processes.

Engineering a Better Fusion

At the heart of the innovation is the transition from traditional materials like PEEK (polyether ether ketone) to a sophisticated, 3D-printed titanium structure. For years, PEEK has been a go-to material for spinal cages due to its bone-like elasticity and radiolucency, which allows surgeons to see through it on X-rays. However, 3D-printed porous titanium offers a new set of advantages that Intelivation has sought to maximize.

The manufacturing process allows for the creation of a nanolattice structure—an intricate, microscopic scaffolding with micropores that mimics the body's own trabecular bone. This complex architecture is engineered to encourage osteointegration, where bone cells actively grow onto and into the implant's surface. Scientific studies on similar porous titanium implants have shown they can create a more favorable environment for bone cell adhesion and proliferation, potentially leading to faster and more robust fusions.

Intelivation's design also incorporates a 'scalloped wall architecture.' This feature allows the device to hold one of the highest volumes of bone graft material available in a cervical cage while simultaneously reducing the implant's overall metal content. More space for graft material provides a greater opportunity for a solid fusion to form between the vertebrae. The reduced metal is not just for weight; it directly addresses a common problem with metallic implants.

Dr. Victor Hsu, the first surgeon to implant the device, highlighted this specific benefit. "This is an exciting new design, and I believe its reduced metal structure may help minimize imaging artifact and improve post-operative visualization," he commented. Metallic implants can create significant distortion on MRI and CT scans, making it difficult for surgeons to accurately assess the healing process. By minimizing these artifacts, the Advantage-C™ Ti3D could provide doctors with a clearer picture of the fusion's progress, enabling better patient care.

From the Lab to the Operating Room

The technical specifications of a new medical device ultimately matter because of their impact on patient outcomes. For individuals undergoing an anterior cervical discectomy and fusion (ACDF), the goal is not only to stabilize the spine but to relieve pain and restore function and quality of life. The features engineered into the Advantage-C™ Ti3D are directly aimed at these clinical endpoints.

A more reliable and rapid fusion process, facilitated by the nanolattice structure, could mean a quicker recovery and a lower chance of failed fusion, which can lead to persistent pain and the need for revision surgery. Furthermore, the device is offered with a range of lordotic options—different angles built into the cage to help restore the natural, healthy curve of the cervical spine. This is a critical factor in achieving long-term surgical success and preventing adjacent segment disease, a condition where the vertebrae above and below the fusion site break down due to altered spinal mechanics.

Dr. Ripul Panchal of the American NeuroSpine Institute, who was also quoted in the announcement, underscored this aspect. "I anticipate that its novel design will deliver outstanding clinical results for my patients," he stated. "Additionally, the range of lordotic options will be beneficial in addressing some of my more challenging cases." This ability to tailor the implant to individual patient anatomy is a key advantage of modern device design.

The credibility of the initial surgeon adds weight to the launch. Dr. Hsu is a highly respected, board-certified orthopedic surgeon specializing in complex and minimally invasive spine surgery, with a history of participation in FDA trials. His early adoption and positive commentary signal a vote of confidence from a key opinion leader in the field.

A Strategic Move in a Competitive Market

The launch of the Advantage-C™ Ti3D is not just a clinical milestone; it is a strategic one for Intelivation Technologies. The company operates in the highly competitive spinal implant market, which is populated by multi-billion dollar giants and a host of innovative smaller firms. For a company that describes itself as 'dedicated to research and development,' successfully bringing a 'paradigm-changing' product from concept to clinical reality is the ultimate validation of its business model.

Amit Sinha, President of Intelivation Technologies, framed the launch in the context of this long-term vision. "The Advantage-C™ Ti3D represents a significant advancement in cervical fusion technology," he said. "We believe its unique design has the potential to improve patient outcomes, and we look forward to collaborating with our surgeon partners while generating post-market clinical data to further evaluate its performance."

This commitment to generating post-market data is crucial. While the device's design is based on sound scientific principles, its long-term performance in a large patient population is what will ultimately determine its place in the market. By actively planning to collect and publish this data, Intelivation is building a foundation for evidence-based adoption by the wider surgical community. This first implantation serves as the starting gun for that critical data-gathering process, transitioning the device from a promising concept to a clinically scrutinized tool.